When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Use of erythropoiesis-stimulating agents in US cancer patients undergoing chemotherapy has increased 10-fold since their introduction, yet there’s been no associated decline in…
NEW YORK (Reuters Health) – After breast-conserving surgery for invasive cancer, mammographic density is a risk factor for local recurrence, particularly in women who don’t undergo radiotherapy, investigators…
NEW YORK (Reuters Health) – In patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN), the survival benefit of adding cetuximab to radiotherapy is still…
NEW YORK (Reuters Health) – In women treated for small (1 cm or less), node-negative breast cancers, HER2 positivity is strongly linked to recurrence and poorer disease-free survival,…
NEW YORK (Reuters Health) – Contrary to previous assertions, low total cholesterol is not a cause of cancer, two separate studies show. Furthermore, a lower total cholesterol level…
NEW YORK (Reuters Health) – Intravenous infusions of iron sucrose before planned colorectal cancer surgery does not reduce perioperative blood transfusions, according to a report in the British…
NEW YORK (Reuters Health) – Men with localized prostate cancer treated with external beam radiotherapy (EBRT) are apt to have better sexual function afterward than men treated with…
NEW YORK (Reuters Health) – Women who regularly use nonsteroidal anti-inflammatory drugs (NSAIDs) have better survival after a colorectal cancer (CRC) diagnosis, research indicates. “A wide body of…
NEW YORK (Reuters Health) – In patients with newly diagnosed multiple myeloma, combining the thalidomide analog lenalidomide with low-dose dexamethasone led to better short-term survival than lenalidomide plus…
NEW YORK (Reuters Health) – Iatrogenic preterm delivery is common among women diagnosed with invasive cancer during pregnancy, a new multicenter study shows. The study, published online in…
